THE EFFECT OF METFORMIN MONOTHERAPY ON BIOCHEMICAL PARAMETERS ASSOCIATED WITH DIABETES MELLITUS, KIDNEY, CARDIAC, LIVER, THYROID, AND REPRODUCTIVE ORGAN FUNCTIONS IN PRE- AND POST-MENOPAUSE WOMEN WITH TYPE 2 DIABETES MELLITUS

Arun Kumar D; Arivazhagan R; Sudhandiran G; Sangeetha R; Swaminathan S

doi:10.22159/ajpcr.2018.v11i3.23447

Authors

Arun Kumar D Department of Biochemistry, Vels University, Pallavaram, Chennai - 600 117, Tamil Nadu, India.
Arivazhagan R Department of Biochemistry, Cancer Institute Adyar, Chennai - 600 020, Tamil Nadu, India.
Sudhandiran G Department of Biochemistry, University of Madras, Guindy Campus, Chennai - 600 025, Tamil Nadu, India.
Sangeetha R Department of Biochemistry, Vels University, Pallavaram, Chennai - 600 117, Tamil Nadu, India.
Swaminathan S Department of Biochemistry, Apollo Speciality Hospitals, Vanagaram, Chennai - 600 095, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i3.23447

Keywords:

Diabetes mellitus, Metformin, Menopause, PG, Glycosylated hemoglobin, Chronic kidney disease, Cardiovascular disease, Thyroidstimulating hormone, Luteinizing hormone, Follicle stimulating hormone, Prolactin

Abstract

Â Objective: The aim of this study was to find out the alterations in biochemical parameters associated with the functioning of kidney, cardiac, liver, thyroid, and reproductive organs in pre- and post-menopause Type 2 diabetes mellitus (T2DM) women treated with metformin monotherapy (MMT) and to select a set of biochemical tests as routine to evaluate the functions of the above organs at regular intervals of time based on the levels of various biochemical parameters during a period of 1 year at 6 and 12 months.

Method: A total of 100 T2DM patients (50 pre- and 50 post-menopause women) who visited Apollo Speciality Hospitals Vanagaram, Sugar Clinic, and who were on treatment with MMT and 100 (50 pre- and 50 post-menopause age-matched non-diabetic women) were enrolled for this study. Fully automated analyzers and reagents and controls were used for all the assays to ensure the validity of the results obtained. GraphPad online calculator was used to calculate t and p values.

Results: MMT for menopause women with T2DM had improved the diabetic parameters, and the levels of fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), and glycosylated hemoglobin (HbA1c) have dropped from 179.48 mg/dL, 270.8 mg/dL, and 8.75% at diagnosis to 135.36, 199.45, and 7.05, respectively, after 12 months of MMT. In the case of post-menopause, the corresponding levels were 180.6, 263.2, and 8.85 to 133.79, 189.06, and 6.68%, respectively, and all the five organ functions were also not altered as the parameters tested for each organ function returned to normal. The drop in all the parameters levels was significant compared to the levels at diagnosis and the p values ranged from <0.01 to<0.0001.

Conclusion: Metformin treatment has shown very good improvement in the progressive reductions in the levels of FPG, PPPG, and HbA1c as well as maintaining the functions of kidney, cardiac, liver, thyroid, and reproductive organs to near normal as per the associations of these organ-specific parameters before and after 6 and 12 months of MMT.

Downloads

Download data is not yet available.

Author Biography

Arun Kumar D, Department of Biochemistry, Vels University, Pallavaram, Chennai - 600 117, Tamil Nadu, India.

Sr Consultant and Head

References

Sjoberg-Tuominen L, Tiitinen A. Menopause in a diabetic. Duodecim 2009;125:2689-94.

TschÃ¶pe D, Hanefeld M, Meier JJ, Gitt AK, Halle M, Bramlage P, et al. The role of co-morbidity in the selection of antidiabetic pharmacotherapy in Type-2 diabetes. Cardiovasc Diabetol 2013;12:62.

Fung CS, Wan EY, Wong CK, Jiao F, Chan AK. Effect of metformin monotherapy on cardiovascular diseases and mortality: A retrospective cohort study on Chinese Type 2 diabetes mellitus patients. Cardiovasc Diabetol 2015;14:137.

Ibrahim R. Diabetes mellitus Type II: Review of oral treatment options. Int J Pharm Pharmsci 2010;2 Suppl 1:21-30.

Ingle PV, Talele GS. Comparative effects of metformin in combination with glimepiride and glibenclamide on lipid profile in Indian patients with Type 2 diabetes mellitus. Int J Pharm Pharm Sci 2011;3 Suppl 5:472-4.

Ioannidis I. Diabetes treatment in patients with renal disease: Is the landscape clear enough? World J Diabetes 2014;5:651-8.

Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: Metabolism and clinical practice. Curr Drug Metab 2011;12:57-69.

Fadini GP, Iori E, Marescotti MC, de Kreutzenberg SV, Avogaro A. Insulin-induced glucose control improves HDL cholesterol levels but not reverse cholesterol transport in Type 2 diabetic patients. Atherosclerosis 2014;235:415-7.

Khalaf BH, Abdulridha MK, Kadhim KA, Hussain SR. Influence of larged aily doses of metformin on the expression of interleukin-1B and C-reactive protein in Type 2 diabetes patients. Int J Pharm Pharm Sci 2014;6:506-9.

Verma RK, Tripathi P, Pandey AK. Role of pioglitazone on progression of atherosclerosis in prediabetes: A mini review. Int J Pharm Pharm Sci 2014;6:13-5.

Mahdy Ali K, Wonnerth A, Huber K, Wojta J. Cardiovascular disease risk reduction by raising HDL cholesterol â€“ current therapies and future opportunities. Br J Pharmacol 2012;167:1177-94.

Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Devereux RB, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The strong heart study. Arterioscler Thromb Vasc Biol 2000;20:830-5.

Daher J, Martin M, Rousseau A, Nuyens V, Fayyad-Kazan H, Van Antwerpen P, et al. Myeloperoxidase oxidized LDL interferes with endothelial cell motility through miR-22 and hemeoxygenase induction: Possible involvement in reendothelialization of vascular injuries mediators inflamm 2014;2014:134635.

Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: The quebec cardiovascular study. Arch Intern Med 2001;161:2685-92.

Mahto M, Chakraborthy B, Gowda SH, Kaur H, Vishnoi G, Lali P. Are hsCRP levels and LDL/HDL ratio better and early markers to unmask onset of dyslipidemia and inflammation in asymptomatic subclinical hypothyroidism. Indian J Clin Biochem 2012;27:284-9.

Halle M, Berg A, Baumstark MW, KÃ¶nig D, Huonker M, Keul Joseph, et al. Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels. Atherosclerosis 1999;143:185-92.

Yoo J, Lee S, Kim K, Yoo S, Sung E, Yim J, et al. Relationship between insulin resistance and serum alanine aminotransferase as a surrogate of NAFLD (nonalcoholic fatty liver disease) in obese Korean children. Diabetes Res Clin Pract 2008;81:321-6.

Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of Type 2 diabetes. Diabetes 2002;51:1889-95.

Lee SY, Sung E, Chang Y. Elevated serum gamma-glutamyltransferase is a strong marker of insulin resistance in obese children. Int J Endocrinol 2013;2013:578693.

Inoue K, Matsumoto M, Miyoshi Y, Kobayashi Y. Elevated liver enzymes in women with a family history of diabetes. Diabetes Res Clin Pract 2008;79:e4-7.

Martins MC, Faleiro LL, Afonso B, Fonseca A. Association of gamma glutamyltransferase, metabolic syndrome and cardiovascular risk. Acta Med Port 2010;23:579-88.

Karimifar M, Aminorroaya A, Amini M, Mirfendereski T, Iraj B, Feizi A, et al. Effect of metformin on thyroid stimulating hormone and thyroid volume in patients with prediabetes: A randomized placebo-controlled clinical trial. J Res Med Sci 2014;19:1019-26.

Pappa T, Alevizaki M. Metformin and thyroid: An update. Eur Thyroid J 2013;2:22-8.

Rajput R, Saini M, Rajput M, Shankar V. Effects of metformin on thyroid function in patients of subclinical hypothyroidism. J Endocrinol Metab 2013;3:105-10.

Metcalf MG, Donald RA, Livesey JH. Pituitary-ovarian function in normal women during the menopausal transition. Clin Endocrinol (Oxf) 1981;14:245-55.

Weiss G, Skurnick JH, Goldsmith LT, Santoro NF, Park SJ. Menopause and hypothalamic-pituitary sensitivity to Estrogen. JAMA 2004;292:2991-6.

McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JE, et al. Pre diagnostic circulating follicle stimulating hormone (FSH) concentrations and ovarian cancer risk. Maturitas 2012;71:55-61.

Beydoun H, Beydoun M, Wiggins N, Stadtmauer L. Relationship of Obesity-related disturbances with LH/FSH ratio among post-menopausal women with United states. Maturitas 2012;71:55-61.

Kapia EW, Chojnacki J, Stepien A, Wachowska-Kelly P, Klupinska G, Chojnacki C. Melatonin and female - Hormone secretion in post-menopausal women. Int J Mol Sci 2015;16:1030-42.

Balint-Peric LA, Prelevic GM. Changesin prolactin leels with the menopause; The effect of Estrogen/Androgen and calcitonin treatment. Gynecol Endocrinol 1997;11:275-80.

Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 2001;54:295-300.